CSBR Champions Oncology Inc
Price (delayed)
$7.31
Market cap
$101.07M
P/E Ratio
15.55
Dividend/share
N/A
EPS
$0.47
Enterprise value
$104.31M
Champions Oncology is a data-driven research organization that leverages an oncology research center of excellence to develop transformative technology and accelerate oncology research and development. This technology ranges from computational-based
Highlights
The net income has soared by 166% YoY
The company's EPS has surged by 165% YoY
Key stats
What are the main financial stats of CSBR
Market
Valuations
Earnings
Shares outstanding
13.83M
Market cap
$101.07M
Enterprise value
$104.31M
Price to earnings (P/E)
15.55
Price to book (P/B)
18.47
Price to sales (P/S)
1.71
EV/EBIT
16.3
EV/EBITDA
12.87
EV/Sales
1.78
Revenue
$58.59M
Gross profit
$30.22M
Operating income
$6.29M
Net income
$6.43M
EBIT
$6.4M
EBITDA
$8.1M
Free cash flow
-$1.32M
Per share
Balance sheet
Liquidity
EPS
$0.47
EPS diluted
$0.44
Free cash flow per share
-$0.1
Book value per share
$0.4
Revenue per share
$4.28
TBVPS
$2.21
Total assets
$30.63M
Total liabilities
$25.16M
Debt
$6.44M
Equity
$5.47M
Working capital
-$173,000
Debt to equity
1.18
Current ratio
0.99
Quick ratio
0.96
Net debt/EBITDA
0.4
Margins
Efficiency
Dividend
EBITDA margin
13.8%
Gross margin
51.6%
Net margin
11%
Operating margin
10.7%
Return on assets
24%
Return on equity
656.7%
Return on invested capital
60.3%
Return on capital employed
59.5%
Return on sales
10.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CSBR stock price
How has the Champions Oncology stock price performed over time
Intraday
-7.47%
1 week
-7.7%
1 month
-19.76%
1 year
45.62%
YTD
-14.7%
QTD
-15.78%
Financial performance
How have Champions Oncology's revenue and profit performed over time
Revenue
$58.59M
Gross profit
$30.22M
Operating income
$6.29M
Net income
$6.43M
Gross margin
51.6%
Net margin
11%
The net income has soared by 166% YoY
The company's operating income has surged by 165% YoY
The net margin has soared by 156% YoY
The operating margin has soared by 155% YoY
Growth
What is Champions Oncology's growth rate over time
Valuation
What is Champions Oncology stock price valuation
P/E
15.55
P/B
18.47
P/S
1.71
EV/EBIT
16.3
EV/EBITDA
12.87
EV/Sales
1.78
The company's EPS has surged by 165% YoY
CSBR's P/B is 72% below its 5-year quarterly average of 67.0
The price to sales (P/S) is 22% lower than the 5-year quarterly average of 2.2 but 14% higher than the last 4 quarters average of 1.5
The revenue has grown by 19% YoY and by 9% from the previous quarter
Efficiency
How efficient is Champions Oncology business performance
CSBR's ROE has soared by 177% YoY
The ROA has soared by 174% YoY
The company's return on invested capital has surged by 164% YoY
The company's return on sales has surged by 156% YoY
Dividends
What is CSBR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CSBR.
Financial health
How did Champions Oncology financials performed over time
The total assets is 22% greater than the total liabilities
CSBR's quick ratio has surged by 71% year-on-year and by 37% since the previous quarter
Champions Oncology's current ratio has surged by 65% YoY and by 32% QoQ
The debt is 18% higher than the equity
The debt to equity has soared by 131% YoY but it has plunged by 88% from the previous quarter
The debt fell by 17% YoY and by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.